Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.81 |
| ▸ | ADAM17 | P78536 | 20/20 | 0.81 |
| ▸ | MMP1 | P03956 | 18/20 | 0.81 |
| ▸ | MMP9 | P14780 | 5/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940979 | 0.97 | MMP13 (0.82) | MMP13ADAM17MMP1MMP9 | |
| Dimethylamine SCHEMBL3939312 | 0.92 | MMP13 (0.70) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6641966 | 0.91 | MMP13 (0.83) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3939993 | 0.90 | MMP13 (1.00) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6610996 | 0.90 | MMP13 (0.71) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3944111 | 0.89 | MMP13 (0.70) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3940219 | 0.89 | MMP13 (0.85) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL4028722 | 0.89 | MMP13 (0.69) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3943727 | 0.88 | MMP13 (0.69) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3944552 | 0.88 | MMP13 (0.74) | MMP13ADAM17MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | claimed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | claimed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | MMP13 246/4885ADAM17 9/4885MMP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.